Immune System Regulation Holding AB and Isomerase Therapeutics Ltd. sign Acquisition and License Agreement based on the next generation of immune regulatory drug candidates
 
ISR Holding AB and Isomerase Therapeutics Ltd. Today signed an acquisition and license agreement, under which ISR acquired rights to the next generation of immune regulatory drug candidates (named ISR50).
 
Following screening of a part of the proprietary Isomerase compound library, ISR and Isomerase scientists discovered a group of potent immune regulatory molecules. Earlier this year and based on these molecules and its applications, both companies filed several mutual patents. The license part of the agreement also gives ISR Holding AB the rights to use Isomerase´s technology platform to generate these molecules.
 
“Preclinical testing of the acquired and potential drug candidates has been very encouraging, which means that we through this acquisition and full ownership of the molecules that have been patented, have built a broader product portfolio and a future opportunity to create significant value for the company”, says Mikael Brönnegård, CEO.
 
“We are delighted that ISR have acquired these exciting molecules and are confident that they are the right partner to take them into the clinic.” Said Dr Matt Gregory, CEO of Isomerase Therapeutics. “We look forward to supporting them through this process and are excited by the great potential they have across a number of therapeutic areas.”